As a leading supplier of oligonucleotides, BOC Sciences is committed to providing our customers with comprehensive modification and labeling, offering affordable custom oligonucleotides or GalNAc-oligonucleotide conjugates.
GalNAc-oligonucleotide conjugation is a method of covalently binding oligonucleotides to N-acetylgalactose (GalNAc), thereby altering its molecular structure and improving the distribution and stability of the drug in the liver. Specifically, GalNAc is a high-affinity ligand that enters the hepatocytes of the liver and is recognized and bound by the GalNAc receptor in the liver, thus enabling target delivery.
GalNAc-oligonucleotide conjugation requires multiple steps. First, an oligonucleotide molecule needs to be designed and synthesized. Then, a C3-GalNAc modifier is introduced at the 3' end of the molecule or a C2 or C5 modifier is introduced directly within the oligonucleotide molecule to modify GalNAc. Next, activation is performed and GalNAc-oligonucleotide is reacted with an activator to form a new compound covalently linked to GalNAc-oligonucleotide. Finally, the compounds were purified and prepared into drugs using relevant methods.
GalNAc-oligonucleotide conjugation has been widely used in the treatment of genetic diseases such as liver fibrosis, lipid-like deposits and hepatitis C. Among them, alkylated and 2'F modified nucleotides as the development direction can greatly enhance the biostability and targeting of GalNAc-oligonucleotide conjugation.
| Service | GalNAc-Oligonucleotide Conjugation |
| Customer provides | Oligonucleotide sequence |
| Purification | QC analysis by MS, HPLC, or PAGE |
| Delivery | Typical delivery is lyophilized samples in individual vials that are fully labeled |
| Request a Quote | Inquiry |

GalNAc-oligonucleotide conjugation involves attaching N-acetylgalactosamine (GalNAc) to oligonucleotides, enhancing their stability and targeting ability, especially for liver delivery. This method improves drug distribution and efficacy, particularly for liver-specific diseases.
GalNAc acts as a high-affinity ligand that binds to the GalNAc receptors on hepatocytes, facilitating targeted delivery to liver cells. This targeted mechanism significantly improves the efficiency of treatments aimed at liver-related diseases.
GalNAc-oligonucleotide conjugation enhances the stability, bioavailability, and specificity of oligonucleotides, particularly for liver-targeted therapies. It improves drug delivery efficiency and reduces off-target effects.
